Category: Correspondence

Did Cannabis Kill the Baby?

Constance McLaughlin-Miley, PharmD,  forwarded this story from the Daily Mail November 19: “First ever fatal marijuana overdose reported in Colorado.” Jeffrey Hergenrather, MD, responds: This is the most information that I’ve seen so far of this news splash. The death occurred at least two years ago.  Though a 7.8 ng/ml level of THC was revealed, I question which cannabinoids are being lumped here —11-OH THC, THC-COOH— and whether any other drugs may have been found in his plasma. The seizure activity is particularly concerning as well as aspiration (tried to vomit) and other complications.  There is also sudden death...

Read More

Correspondence 11/21/17

From Manan Travedi, MD, of the National Physicians Alliance: Just a few days ago President Trump nominated pharmaceutical executive, Alex Azar, to be the next Secretary of the Health and Human Services Department. We believe Mr. Azar’s deep ties to the pharmaceutical industry disqualify him from being an independent voice for our nation’s health care system. Moreover, his previous work in the public sector show that he has no inclination to improve upon the gains we have made in the Affordable Care Act and further efforts to achieve truly universal health care. Drug corporations already have undue influence over...

Read More

MJ Recommendation Won’t Save Your Job

An item posted November 10 by Tom Angell, forwarded by Dale Gieringer with the comment, “But Rx opiates are okay.” Using medical cannabis with a doctor’s recommendation in accordance with state law is no excuse for failing a drug test, the Trump administration says in a new clarification of federal rules. “The term ‘prescription’ has become more loosely used in recent years,” the U.S. Department of Transportation (DOT) writes in a ruling scheduled to be published in the Federal Register on Monday. “Some state laws allowing marijuana use the term ‘prescription,’ even though a recommendation for someone to use marijuana under...

Read More

Mass Production of ‘Minor’ Cannabinoids —via Yeast

From the New Scientist: A non-psychoactive compound found in marijuana plants called cannabidivarin (CBDV) has shown promise in the treatment of severe cases of epilepsy. However, to treat just 10 per cent of people with epilepsy would require around 1500 tons of pure CBDV. To obtain this amount using current methods, you would need to plant large quantities of marijuana and extract their small supply of CBDV. “There’s so little of this chemical in plants it would actually be impossible to harvest it by traditional means,” says Kevin Chen, who runs Hyasynth Bio, a start-up in Montreal, Canada. That’s...

Read More

SCC Wants Terpenoid Testing in California

Bureau of Cannabis Control Attention: Sara Gardner 1625 North Market Boulevard, Suite S-202 Sacramento, CA 95834 September 28, 2017 Subject: Comment on the draft CEQA IS/ND report Dear Ms. Gardner, We are writing as board members of the Society of Cannabis Clinicians (SCC)1. We have recently reviewed a copy of the draft CEQA document that has been submitted for public comment. We are deeply concerned about section 3.5.2, Substances Requiring Analysis, Terpenes and Terpenoids. While Prop 64 and previous State laws on medical cannabis, required testing for “The terpenes described in the most current version of the cannabis inflorescence monograph...

Read More